Research
Hormonal
In trials without SGLT2 inhibitors, there was a significant reduction of 21% in new-onset AF.
Semaglutide may be more effective in reducing AF risk when not used with SGLT2 inhibitors.
StrongSupportsmedium confidence
In trials without Sodium-Glucose Co-Transporter 2 inhibitors (SGLT2i) concomitant therapy, there was a significant reduction of 21% in new-onset AF (OR 0.79, 95% CI, 0.63-0.99; p=0.04).
Why this rating
Based on a meta-analysis of multiple RCTs.
Source
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials
Arturo Cesaro et al. · European Journal of Preventive Cardiology · 2025
Meta-analysisCited 29×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →